Ocera Therapeutics' Reverse Merger Round

Ocera Therapeutics raised a round of funding on July 15, 2013. Investors include Tranzyme Pharma.

Ocera Therapeutics is focused on the development and commercialization of therapeutics for gastrointestinal and liver diseases. The company's portfolio consists of OCR-002 and AST-120. OCR-002 is an a…

Articles about Ocera Therapeutics' Reverse Merger Round: